ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,040.04
1.10%
Dow Jones
43,297.03
0.91%
US Dollar vs MXN
20.1693
0.00%
Brent Oil
73.285
0.00%
Bitcoin
98,318.84
-0.37%
Pepperstone
Advertisement
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. KalVista Pharmaceuticals Inc (KALV) Cotización

KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc (KALV)

NASDAQ
8.76
-0.07
(-0.79%)
Al cierre: 24 Diciembre 3:00PM
Delayed by 15 minutes
8.76
0.00
( 0.00% )
Fuera de horario: 4:00PM
Delayed by 15 minutes

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Estadísticas y detalles clave

Último Precio
8.76
Postura de Compra
8.53
Postura de Venta
8.90
Volume Operado de la Acción
125,256
8.475 Rango del Día 8.825
7.97 Rango de 52 semanas 16.88
Capitalización de Mercado [m]
432.902M
Precio Anterior
8.83
Precio de Apertura
8.82
Hora
5
@
8.7
Última hora de negociación
Volumen financiero
US$ 1,092,657
Precio Promedio Ponderado
8.7234
Volumen promedio (3 m)
384,261
Acciones en circulación
49,417,986
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-3.42
Beneficio por acción (BPA)
-2.56
turnover
-
Beneficio neto
-126.64M

Acerca de KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angio... KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.kalvista.com
Sede
Dover, Delaware, USA
Fundado
-
KalVista Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KALV. The last closing price for KalVista Pharmaceuticals was US$8.83. Over the last year, KalVista Pharmaceuticals shares have traded in a share price range of US$ 7.97 to US$ 16.88.

KalVista Pharmaceuticals currently has 49,417,986 shares in issue. The market capitalisation of KalVista Pharmaceuticals is US$436.36 million. KalVista Pharmaceuticals has a price to earnings ratio (PE ratio) of -3.42.

KALV Últimas noticias

Más noticias

Form 8-K - Current report

16 Diciembre 2024
Edgar (US Regulatory)

KalVista Appoints Jeb Ledell as Chief Operating Officer

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a...

16 Diciembre 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

09 Diciembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

05 Diciembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

05 Diciembre 2024
Edgar (US Regulatory)

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

–Continuing to build commercial infrastructure; on track for potential sebetralstat launch in Q2 2025– –Multinational regulatory submissions for sebetralstat position Company to transform...

05 Diciembre 2024
Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted five newly-hired employees inducement options to purchase...

04 Diciembre 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

27 Noviembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

27 Noviembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

26 Noviembre 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.18-2.013422818798.949.37.976841598.49893453CS
4-1.11-11.24620060799.8710.487.974157319.00037535CS
12-2.67-23.359580052511.4312.857.9738426110.14614557CS
26-3.01-25.573491928611.7715.57.9737251411.29279329CS
52-2.98-25.383304940411.7416.887.9747262112.39954449CS
156-5.71-39.460953697314.4717.3454.1234504210.68459476CS
260-8.71-49.856897538617.47454.1231562715.75822749CS

KALV - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de KalVista Pharmaceuticals?
El precio actual de las acciones de KalVista Pharmaceuticals es US$ 8.76
¿Cuántas acciones de KalVista Pharmaceuticals están en circulación?
KalVista Pharmaceuticals tiene 49,417,986 acciones en circulación
¿Cuál es la capitalización de mercado de KalVista Pharmaceuticals?
La capitalización de mercado de KalVista Pharmaceuticals es USD 436.36M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de KalVista Pharmaceuticals?
KalVista Pharmaceuticals ha negociado en un rango de US$ 7.97 a US$ 16.88 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de KalVista Pharmaceuticals?
El ratio precio/beneficio de KalVista Pharmaceuticals es -3.42
¿Cuál es la moneda de reporte de KalVista Pharmaceuticals?
KalVista Pharmaceuticals presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de KalVista Pharmaceuticals?
El último beneficio anual de KalVista Pharmaceuticals es USD -126.64M
¿Cuál es la dirección registrada de KalVista Pharmaceuticals?
La dirección registrada de KalVista Pharmaceuticals es 3500 S DUPONT HWY, DOVER, DELAWARE, 19901
¿Cuál es la dirección del sitio web de KalVista Pharmaceuticals?
La dirección del sitio web de KalVista Pharmaceuticals es www.kalvista.com
¿En qué sector industrial opera KalVista Pharmaceuticals?
KalVista Pharmaceuticals opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
BAOSBaosheng Media Group Holdings Ltd
US$ 7.10
(310.40%)
58.74M
HOURHour Loop Inc
US$ 4.40
(207.69%)
97.42M
GTIGraphjet Technology
US$ 0.61
(168.72%)
265.48M
CREVCarbon Revolution Public Ltd
US$ 9.16
(135.48%)
26.95M
AVGRAvinger Inc
US$ 1.45
(125.72%)
107.53M
SLGLSol Gel Technologies Ltd
US$ 0.9798
(-40.62%)
3.07M
DRCTDirect Digital Holdings Inc
US$ 3.71
(-32.55%)
23.82M
CHEKCheck Cap Ltd
US$ 1.55
(-31.11%)
3.49M
SYTASiyata Mobile Inc
US$ 0.5178
(-30.83%)
2.63M
BTFValkyrie ETF Trust II CoinShares Bitcoin and Ether Stratagy ETF
US$ 15.47
(-30.38%)
147.98k
SVMHSRIVARU Holding Ltd
US$ 0.0338
(20.71%)
280.27M
GTIGraphjet Technology
US$ 0.61
(168.72%)
265.48M
LITMSnow Lake Resources Ltd
US$ 0.5849
(52.84%)
181.22M
LCIDLucid Group Inc
US$ 3.20
(3.23%)
108.75M
RGTIRigetti Computing Inc
US$ 11.35
(3.56%)
108.38M

KALV Discussion

Ver más
Monksdream Monksdream 6 meses hace
KALV 10Q expected July 5
👍️0
Monksdream Monksdream 9 meses hace
KALV over $10
👍️0
Monksdream Monksdream 10 meses hace
KALV new 52=week high
👍️0
clydesur clydesur 10 meses hace
INSIDER PURCHASE / SYNDICATE

KALV - 10% OWNER Venrock Healthcare P 86,048 $14.618
👍️0
Monksdream Monksdream 11 meses hace
KALV new 52 week high
👍️0
Monksdream Monksdream 12 meses hace
KALV new 52 week high
👍️0
Femto99 Femto99 4 años hace
I would not even buy the shares at $20.
👍️0
Femto99 Femto99 4 años hace
All in puts!
👍️0
Stock_Barber Stock_Barber 4 años hace
Boom!

Killed it with puts today!

👍️0
ClayTrader ClayTrader 4 años hace
* * $KALV Video Chart 02-09-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
Stock_Barber Stock_Barber 4 años hace
This company is a disaster...

👍️0
make it happen make it happen 4 años hace
The company is delinquent.
👍️0
make it happen make it happen 4 años hace
? lol

Profitability
Profit Margin 0.00%
Gross Profit (ttm) $-27.5M
EBITDA $-48.38M
Net Income Avi to Common (ttm) $-37.12M
Diluted EPS (ttm) -2.08

Book Value Per Share (mrq) $3.63

Going to keep diluting more and more
👍️0
make it happen make it happen 4 años hace
They are hemorrhaging money. Have pretty much zero revenue. They still have hundreds of millions to spend of your money until phase 3 and beyond.

Operating Margin (ttm) -905.50%

Management Effectiveness

Return on Assets (ttm) -32.60%
Return on Equity (ttm) -45.61%

Revenue  $5.4M
Revenue Per Share  $0.30

👍️0
TFMG TFMG 5 años hace


$KALV Kalvista Pharma Trend Break



Major Downtrend broken
Broken above 200ma
Volume increased
MACD reversed
RSi in bullish uptrend



👍️0
whytestocks whytestocks 6 años hace
News: $KALV KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Daniel Soland has been appointed to its Board of Directors effective immediately. Mr...

Find out more https://marketwirenews.com/news-releases/kalvista-pharmaceuticals-appoints-daniel-b-soland-to-board-of-directors-8035190.html
👍️0
whytestocks whytestocks 6 años hace
News: $KALV KalVista Pharmaceuticals to Present at Needham Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Needham Healthcare Conference on Wednesday, April 10, 2019, a...

Read the whole news https://marketwirenews.com/news-releases/kalvista-pharmaceuticals-to-present-at-needham-healthcare-conference-7939130.html
👍️0
stocktrademan stocktrademan 6 años hace
KALV buy 28.87



normal chart







log chart






👍️0
whytestocks whytestocks 6 años hace
News: $KALV KalVista Pharmaceuticals Reports Fiscal Third Quarter Results

– Oral Hereditary Angioedema (HAE) Candidate KVD900 Phase 2 Trial Progressing – – Intravitreal Diabetic Macular Edema (DME) Candidate KVD001 Phase 2 Trial Completion Expected H2 2019 – – Oral Plasma Kallikrein Inhibitor Candidate KVD824 Dosi...

Read the whole news https://marketwirenews.com/news-releases/kalvista-pharmaceuticals-reports-fiscal-third-quarter-results-7846828.html
👍️0
countryrapper2000 countryrapper2000 7 años hace
Where is everyone?
👍️0
TheFinalCD TheFinalCD 7 años hace
$17.85 !!


KALV
👍️0
Lone Wolf Lone Wolf 7 años hace
Sniffer rocket ship today!! Wheeee.

KALV
👍️0
TheFinalCD TheFinalCD 7 años hace
$15.50 now ~ keep rollin



$KALV
👍️0
kondziu kondziu 8 años hace
http://m.nasdaq.com/article/sv-life-sciences-advisers-llc-buys-kalvista-pharmaceuticals-sells-raptor-pharmaceutical-cm744623
👍️0
Warchest Warchest 8 años hace
$8.25 now ~ keep rollin
👍️0
ming1234 ming1234 8 años hace
any positive news and volume will move this north
👍️0
Warchest Warchest 8 años hace
LIVE action starting !!!
👍️0
Warchest Warchest 8 años hace
watching close ~
👍️0
Toxic Avenger Toxic Avenger 8 años hace
The way this is dropping, there has to be a lawsuit over the sale of cash at 60% off.
Where are those ambulance chasing securities lawyers?
👍️0
MSparks6 MSparks6 8 años hace
So when will CBYL holders be issued KALV common stock?
👍️0
Toxic Avenger Toxic Avenger 8 años hace
CBYL is now KALV with a 1:14 reverse stock split.

Be very careful for the next few days as until all or most of the CBYL shares are converted to KALV, the only sellers will be private Kal Vista investors, those who bought after the symbol change and professionals. The price is likely to be high until existing CBYL retail holders can sell their shares. In addition, the existing CBYL shares will only represent 20% of the O/S. 80% will be held by the private investors in KVAL.
👍️0
Iam_in Iam_in 8 años hace
$6.00
👍️0
Iam_in Iam_in 8 años hace
New Ticker symbol now: KALV
👍️0
Iam_in Iam_in 8 años hace
Correction : $5.49 PM
👍️0
Iam_in Iam_in 8 años hace
WOW - look at this $0,89---> $4,60

New Ticker name now : KALV

look at NASDAQ - PM
👍️0
Toxic Avenger Toxic Avenger 8 años hace
Apparently the merger deal was approved by a huge margin.

Still don't get it.
👍️0
ClayTrader ClayTrader 8 años hace
* * $CBYL Video Chart 11-21-16 * *

Link to Video - click here to watch the technical chart video
👍️0
beginneer beginneer 8 años hace
Attempting to break 0.72. GL to holders
👍️0
beginneer beginneer 8 años hace
We'll see how this goes. Hopefully back to over a dollar.
👍️0
Toxic Avenger Toxic Avenger 8 años hace
CBYL continuing its upward momentum pre-market.
👍️0
ClayTrader ClayTrader 8 años hace
* * $CBYL Video Chart 11-18-16 * *

Link to Video - click here to watch the technical chart video
👍️0
beginneer beginneer 8 años hace
Oh okay. Im still up for it even if it is a merger. Good thing volume picked up today.
👍️0
Toxic Avenger Toxic Avenger 8 años hace
New buyer? They're not being bought, they're merging with another company and selling their cash at a steep discount.

Maybe the large shareholders decided it's better to take a smaller loss now by liquidating, than wait for a larger loss later and they're voting against the deal.

I can only hope!
👍️0
beginneer beginneer 8 años hace
Somethings fishy going on here. Why the sudden spike in volume? New buyer in sight?
👍️0
Toxic Avenger Toxic Avenger 8 años hace
Fun while it lasted.
👍️0
Toxic Avenger Toxic Avenger 8 años hace
Big bounce today. Anyone know why?
👍️0
Toxic Avenger Toxic Avenger 8 años hace
$700k / month for a company that has only a few execs and no business left???

No wonder they want to merge. If they liquidate, the execs all lose their gravy train.

Maybe that can be part of the class action suit.
👍️0
Toxic Avenger Toxic Avenger 8 años hace
Looks like an attempt to prevent the merger by some shareholders has failed. http://ih.advfn.com/p.php?pid=nmona&article=72839538&symbol=CBYL
👍️0
Toxic Avenger Toxic Avenger 8 años hace
Looks like an attempt to prevent the merger by some shareholders has failed. http://ih.advfn.com/p.php?pid=nmona&article=72839538&symbol=CBYL
👍️0
Toxic Avenger Toxic Avenger 8 años hace
Sadly, I don't think so.
👍️0

Su Consulta Reciente

NASDAQ
KALV
KalVista Pharmaceuticals
LSE
93JM
Asb Bk. 24
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados